Lytix Biopharma AS (STU:6BG) ROE % Adjusted to Book Value: -17.75% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6BG Lytix Biopharma AS STU:6BG
31 GF Score
Price €0.80
GF Value €0.02
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS ROE % Adjusted to Book Value?

Lytix Biopharma AS STU:6BG -3.37% 31 ROE % Adjusted to Book Value is -17.75% as of Mar. 2026. GuruFocus rates STU:6BG with a GF Score™ of 31/100 and a GF Value™ of €0.02. The stock has 2 warning signs investors should review.

Lytix Biopharma AS's ROE % for the quarter that ended in Mar. 2026 was -120.20%. Lytix Biopharma AS's PB Ratio for the quarter that ended in Mar. 2026 was 6.77. Lytix Biopharma AS's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -17.75%.

Lytix Biopharma AS ROE % Adjusted to Book Value Related Terms

Lytix Biopharma AS ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS ROE % Adjusted to Book Value Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -16.17 -15.78 -23.85 -32.67 -6.88

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.89 -3.73 -18.88 -10.33 -17.75

STU:6BG vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Lytix Biopharma AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lytix Biopharma AS ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lytix Biopharma AS's ROE % Adjusted to Book Value falls into.


STU:6BG
31GF Score
Lytix Biopharma AS STU:6BG
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS ROE % Adjusted to Book Value Calculation

Lytix Biopharma AS's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-70.38% / 10.23
=-6.88%

Lytix Biopharma AS's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-120.20% / 6.77
=-17.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -17.75% mean?
Lytix Biopharma AS (STU:6BG) has a ROE % Adjusted to Book Value of -17.75% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's ROE % Adjusted to Book Value too high?
Lytix Biopharma AS's current ROE % Adjusted to Book Value is -17.75%. Overall, Lytix Biopharma AS has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's ROE % Adjusted to Book Value compare to VRTX and REGN?
Lytix Biopharma AS's ROE % Adjusted to Book Value of -17.75% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current ROE % Adjusted to Book Value is -17.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current ROE % Adjusted to Book Value of -17.75%. The stock's GF Value™ is €0.02, compared to a current price of €0.80 — trading 3910% above its estimated fair value. The current ROE % Adjusted to Book Value is -17.75%. Lytix Biopharma AS's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current ROE % Adjusted to Book Value is -17.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.80 is trading 3910% above its estimated GF Value™ of €0.02.

Key valuation signals for STU:6BG:

  • ROE % Adjusted to Book Value: -17.75%
  • GF Value™: €0.02 vs. price of €0.80 (3910% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
31GF Score

Get the complete analysis for STU:6BG

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€0.02
GF Value